|
Originally published In Press as doi:10.1074/jbc.M108390200 on November 27, 2001
J. Biol. Chem., Vol. 277, Issue 8, 6413-6421, February 22, 2002
Dominant-negative Suppression of HNF-1 Results in
Mitochondrial Dysfunction, INS-1 Cell Apoptosis, and Increased
Sensitivity to Ceramide-, but Not to High Glucose-induced Cell
Death*
Hella
Wobser ,
Heiko
Düßmann ,
Donat
Kögel ,
Haiyan
Wang§,
Claus
Reimertz ,
Claes B.
Wollheim§,
Maria M.
Byrne¶ , and
Jochen H. M.
Prehn ¶ **
From the Interdisciplinary Center for Clinical
Research (IZKF), Research Group "Apoptosis and Cell Death," the
¶ Department of Pharmacology and Toxicology, Westphalian
Wilhelms-University, D-48149 Münster, Germany, and the
§ Department of Internal Medicine, Division of Clinical
Biochemistry and Experimental Diabetology, University Medical Center,
CH-1211 Geneva, Switzerland
Received for publication, August 30, 2001, and in revised form, October 30, 2001
 |
ABSTRACT |
Maturity onset diabetes of the young (MODY) 3 is
a monogenic form of diabetes caused by mutations in the transcription
factor hepatocyte nuclear factor (HNF)-1 . We investigated the
involvement of apoptotic events in INS-1 insulinoma cells
overexpressing wild-type HNF-1 (WT-HNF-1 ) or a dominant-negative
mutant (DN-HNF-1 ) under control of a
doxycycline-dependent transcriptional activator. Forty-eight h after induction of DN-HNF-1 , INS-1 cells activated caspase-3 and underwent apoptotic cell death, while cells
overexpressing WT-HNF-1 remained viable. Mitochondrial cytochrome
c release and activation of caspase-9 accompanied
DN-HNF-1 -induced apoptosis, suggesting the involvement of the
mitochondrial apoptosis pathway. Activation of caspases was preceded by
mitochondrial hyperpolarization and decreased expression of the
anti-apoptotic protein Bcl-xL. Transient overexpression of Bcl-xL was
sufficient to rescue INS-1 cells from DN-HNF-1 -induced apoptosis.
Both WT- and DN-HNF-1 -expressing cells demonstrated similar
increases in apoptosis when cultured at high glucose (25 mM). In contrast, induction of DN-HNF-1 highly sensitized cells to ceramide toxicity. In cells cultured at low glucose, DN-HNF-1 induction also caused up-regulation of the cell
cycle inhibitor p27KIP1. Therefore, our data
indicate that increased sensitivity to the mitochondrial apoptosis
pathway and decreased cell proliferation may account for the
progressive loss of -cell function seen in MODY 3 subjects.
 |
INTRODUCTION |
Maturity onset diabetes of the young
(MODY)1 is a monogenic form
of diabetes characterized by early age of onset (<25 years), autosomal
dominant transmission, and primary pancreatic -cell dysfunction (1).
It has been postulated that it may account for ~1-5% of all
diabetes. It results from heterozygous mutations of at least six
different genes, one encoding for the glycolytic enzyme glucokinase
(MODY2) and the others encoding transcription factors hepatocyte
nuclear factor (HNF)-4 (MODY1), HNF-1 (TCF1; MODY3), insulin
promoter factor-1 (IPF-1; MODY4), HNF-1 (TCF2; MODY5), and
NeuroD/ 2 (MODY6). MODY3 is the commonest form of MODY accounting for
65% of MODY cases in the United Kingdom (2).
Phenotypically, most MODY 3 subjects under the age of 10 years have
normal glucose tolerance (2). However, studies in the prediabetic phase
show that insulin secretion is reduced only when plasma glucose
concentrations exceed 8 mM (3). Similar patterns of insulin
secretion are seen in MODY 1 subjects (4) as well as in partially
pancreatectomized rats and dogs (5, 6) suggesting that a reduction in
-cell mass may be contributing to the observed -cell dysfunction.
HNF-1 is a dimeric homeodomain-containing protein that is expressed
in the liver, kidney, intestine, and pancreatic islets (7-9). It is
involved in the regulation of hepatic proteins as well as proteins
affecting carbohydrate metabolism and fatty acid homeostasis (10-13).
HNF-1 gene mutations are found in the promoter region, DNA-binding
domain, and transactivation domain, and lead to a loss of function.
Some mutants such as the most frequently found P291fsinsC also act as
dominant-negative proteins in vitro, i.e. they
retain their DNA-binding domain and form nonfunctional dimers with
wild-type HNF-1 (14, 15). Considerable variation also exists in the
severity of the diabetes (2, 16), with ~30% of MODY3 subjects
eventually requiring insulin therapy.
Homozygous HNF-1 knockout mice develop diabetes with defective
insulin secretory responses to glucose and arginine (11, 12) but normal
responses to KCl (17). These mice also demonstrated an inadequate
-cell mass for the degree of hyperglycemia, as well as a reduction
in the ratio of - to non- cells. Principally, a defect in
-cell mass compensation can be caused by decreased neogenesis/proliferation rate, increased apoptosis rate, or both (18).
Reduction in -cell mass has been observed in several NIDDM animal
models (19-24). There is strong evidence supporting the increase in
-cell apoptosis as a predominant factor resulting in decrease in
-cell mass (19, 21, 25-27).
This study was therefore undertaken to establish whether HNF-1
function plays a role in the control of apoptosis in insulin secreting
cells, and thereby the pathogenesis of MODY3 diabetes. This study
demonstrates that dominant-negative suppression of HNF-1 function in
INS-1 insulinoma cells activates the evolutionary conserved apoptotic
cell death machinery via alterations in gene expression and
mitochondrial function, and increases their sensitivity to ceramide-,
but not to high glucose-induced apoptosis.
 |
EXPERIMENTAL PROCEDURES |
Materials--
N-Acetyl-D-erythrosphingosine
(C2-ceramide) and staurosporine (STS) were purchased from Alexis
(Grünberg, Germany). C2-dihydroceramide was from Biomol (Hamburg,
Germany), and doxycycline from Sigma (Deisenhofen, Germany). The broad
spectrum caspase inhibitor
Z-Val-Ala-Asp(O-methyl)-fluoromethylketone (zVAD-fmk) was
obtained from Enzyme Systems (Dublin, CA). The caspase substrate
acetyl-Asp-Glu-Val-Asp-aminomethylcoumarin (Ac-DEVD-AMC) was purchased
from Bachem (Heidelberg, Germany). All other chemicals came in
analytical grade purity from Promega (Mannheim, Germany) or Roth
(Karlsruhe, Germany).
Cultivation and Treatment of Insulinoma Cells Overexpressing
HNF-1 in an Inducible System--
Rat INS-1 insulinoma cells
overexpressing wild-type HNF-1 (number 15) (WT-HNF-1 ) or a
dominant-negative mutant of HNF-1 (SM6, number 31; DN-HNF-1 )
under control of a doxycycline-dependent transcriptional
activator have been described previously (28). The SM6 mutant contains
a substitution of 83 amino acids in the HNF-1 DNA-binding domain,
resulting in the formation of non-functional heterodimers with
wild-type HNF-1 (29). The level of HNF-1 expression can be
tightly controlled by culturing the cells over defined time periods
with doxycycline (28). Maximal induction of HNF-1 is achieved at a
concentration of 500 ng/ml (28). INS-1 cells conditionally
overexpressing WT-HNF-1 and DN-HNF-1 , as well as parental INS-1
cells were cultured in RPMI 1640 medium (Invitrogen, Germany)
supplemented with 2 mM L-glutamin, 1 mM pyruvate, penicillin (100 units/ml), streptomycin (100 µg/ml), 10% fetal calf serum (PAA, Cölbe, Germany), 10 mM Hepes (pH 7.4), and 50 µM
2-mercaptoethanol. Cells were plated at a density of 6 × 104 cells/cm2. After 36 h, culture medium
was supplemented with 500 ng/ml doxycycline for 6-60 h to induce the
expression of WT- and DN-HNF-1 , respectively. In the experiments
shown in Fig. 6A, the doxycycline treatment was performed in
the presence of varying glucose concentrations (0-25 mM).
In the experiments shown in Fig. 6, B-D, WT- or DN-HNF-1 expression was induced for 14 or 24 h in RPMI 1640 medium, and cells were treated during the last 4 h with C2-ceramide,
C2-dihydroceramide, or vehicle (dimethyl sulfoxide, 0.1%).
Hoechst Staining of Nuclear Chromatin and Evaluation of Cellular
Necrosis--
To observe nuclear changes indicative of apoptosis, the
chromatin-specific dye Hoechst 33258 was used. Cultures were fixed with
4% paraformaldehyde in phosphate-buffered saline (PBS) at 37 °C for
10 min, then permeabilized by treatment with a 19:1 mixture of
ethanol/acetic acid at 20 °C for 15 min. Cells were stained with 1 µg/ml Hoechst 33258 (Sigma) in PBS at room temperature for 20 min.
Hoechst staining was viewed with an Eclipse TE 300 inverted-stage
fluorescence microscope (Nikon, Düsseldorf, Germany) with the
following optics: excitation, 340-380 nm; dichroic mirror, 400 nm;
emission, 435-485 nm. Digital images of equal exposure were acquired
using a 12-bit CCD camera (SPOT-2 camera; Diagnostic Instruments,
Sterling Heights, MI) and SPOT software version 2.2.1. Uptake of the
membrane-impermeant dye propidium iodide (5 µg/ml) was used for the
detection of cellular necrosis (optics: excitation 510-560 nm;
dichroic mirror, 575 nm; emission, >590 nm).
Measurement of Caspase Activity--
Cells were lysed in 200 µl of lysis buffer (10 mM Hepes, pH 7.4, 42 mM KCl, 5 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 0.1 mM
EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 1 µg/ml pepstatin A, 1 µg/ml leupeptin, 5 µg/ml aprotinin, 0.5%
CHAPS). Fifty µl of this lysate was added to 150 µl of reaction
buffer (25 mM Hepes, 1 mM EDTA, 0.1% CHAPS,
10% sucrose, 3 mM dithiothreitol, pH 7.5). The reaction
buffer was supplemented with 10 µM Ac-DEVD-AMC, a fluorigenic substrate cleaved by caspase-3, but also by other executioner caspases including caspase-6 and -7 (30). Accumulation of
AMC fluorescence was monitored over 120 min using a HTS fluorescent plate reader (PerkinElmer Life Sciences, Langen, Germany) (excitation 380 nm, emission 465 nm). Fluorescence of blanks containing no cell
lysate were subtracted from the values. Protein content was determined
using the Pierce Coomassie Plus Protein Assay Reagent (KMF, Cologne,
Germany). Caspase activity is expressed as change in arbitrary
fluorescent units (A.U.) per µg of protein and hour.
Quantification of Mitochondrial Membrane Potential--
The
mitochondrial membrane potential was quantified confocally using an
inverted Olympus IX70 microscope attached to a confocal laser scanning
unit equipped with a 488 nm argon laser and a ×60 oil fluorescence
objective (Fluoview; Olympus, Hamburg, Germany). Cells were cultivated
in 8-well chambered coverglasses (Nalge Nunc, Wiesbaden, Germany).
After treatment with doxycycline, cells were incubated with 25 nM
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine iodide (JC-1; Molecular Probes, Leiden, The Netherlands) in culture medium at 37 °C for 1 h. The cationic dye JC-1 distributes
accross the plasma and mitochondrial membranes according to the Nernst equation. The fluorescence emission sprectrum exhibits a red shift due
to formation of J-aggregates in a concentration-dependent manner in hyperpolarized mitochondria (31). The slides were mounted
onto a microscope stage equipped with a temperature-controlled inlay
(HT200, Minitüb, Tiefenbach, Germany). To prevent evaporation the
media was covered with embryo-tested paraffin oil. Images were obtained
using Fluoview 2.0 software and Kalman averaged from two individual
scans for each time point. After background subtraction the
fluorescence intensity of J-aggregates (>570 nm) was devided by the
intensity of the JC-1 monomers (510-540 nm) for each image.
Quantitative analysis of the images was performed using the UTHSCSA
Image Tool Programm (available from www.maxrad6.uthscsa.edu).
Detection of Cytochrome c Release--
Selective plasma membrane
permeabilization with digitonin was used to analyze the release of
cytochrome c from mitochondria into the cytosol (32). This
method obviates possible artifacts due to mechanical breakage of the
outer mitochondrial membrane by Dounce homogenization. Culture plates
with 106 cells per well were placed on ice. Cells were
washed with ice-cold PBS and subsequently incubated in 100 µl of
permeabilization buffer (210 mM D-mannitol, 70 mM sucrose, 10 mM HEPES, 5 mM
succinate, 0.2 mM EGTA, 100 µg/ml digitonin, pH 7.2) for
5 min. The permeabilization buffer was transferred to a reaction tube
and centrifuged for 10 min at 13,000 × g. The
supernatant was transferred to a new reaction tube and protein content
was determined using the Pierce BCA Micro Protein Assay kit. Equal
amounts of protein were analyzed by Western blot analysis using 15%
SDS-PAGE as described below.
Total RNA Extraction and Northern Blot Analysis--
DN-HNF1
cells were cultured in the presence or absence of 500 ng/ml doxycycline
for 48 h and continued for 8 h at the indicated glucose
concentrations. Total RNA was extracted by the guanidinium thiocyanate/phenol/chloroform method. Total RNA (20 µg) was denatured with glyoxal and dimethyl sulfoxide and separated on 1% agarose gels.
Resolved RNA was blotted to nylon membranes (Hybond-N, Amersham Pharmacia Biotech) by vacuum transfer (VacuGeneXL, Amersham Pharmacia Biotech), followed by UV cross-linking. The membranes were
prehybridized and then hybridized to 32P-labeled random
primed cDNA probes according to standard protocols. cDNA
fragments used as probes for cyclophilin, Bcl-xL, Bax, Bad, Bid, p21,
and p27 mRNA detection were prepared by reverse transcriptase-PCR and confirmed by sequencing. HNF-1 cDNA was obtained from
corresponding expression vector kindly provided by Dr. R. Cortese
(Istituto Di Recerche Di Biologica Molecolare, Pomezia, Italy).
Western Blotting--
Cells were rinsed with ice-cold PBS and
lysed in Tris-buffered saline containing SDS, glycerin, and protease
inhibitors. Protein content was determined using the Pierce BCA Micro
Protein Assay kit. Samples were supplemented with 2-mercaptoethanol and
denaturated at 95 °C for 5 min. An equal amount of protein (20-50
µg) was separated with 5-15% SDS-PAGE and blotted to nitrocellulose
membranes (Protean BA 85; Schleicher & Schuell, Dassel, Germany). The
blots were blocked with 5% nonfat milk in blocking solution (15 mM Tris-HCl, pH 7.5, 200 mM NaCl, and 0.1%
Tween 20) for 2 h at room temperature. Membranes were incubated
overnight at 4 °C with the following primary antibodies: a rabbit
polyclonal anti-HNF-1 antibody diluted 1:5,000 (kindly provided by
Dr. R. Cortese), a mouse monoclonal anti-cytochrome c
antibody (clone 7H8.2C12, 1:1000, Pharmingen Becton Dickinson, Hamburg,
Germany), a rabbit polyclonal anti-active caspase-3 antibody (MF397)
raised against p17/p12 x-ray crystallographic grade recombinant
caspase-3 diluted 1:1,000 (33) kindly provided by Dr. D. W. Nicholson, Merck Frosst, Point Claire-Dorval, Quebec, Canada), a rabbit
polyclonal anti-active caspase-9 antibody (MF445) raised against the
p18 large subunit diluted 1:1,000 (kindly provided by Dr. Nicholson),
and a mouse monoclonal anti- -tubulin antibody (clone DM 1A;
1:10,000, Sigma). Afterward, membranes were washed and incubated with
anti-mouse or anti-rabbit IgG-horseradish peroxidase conjugate
(1:1,000-1:5,000; Promega). Antibody-conjugated peroxidase activity
was visualized using the SuperSignal chemiluminescence reagent
(Pierce). Membranes were stripped in standard stripping buffer (2%
SDS, 62.5 mM Tris-HCl, 100 mM
2-mercaptoethanol, pH 6.8) at 60 °C for 30 min, washed twice and reprobed.
Immunofluorescence Analysis--
Cells were fixed in 4%
paraformaldehyde solution, washed three times with PBS, permeabilized
at room temperature in PBS containing 0.15% Tween 20 for 20 min, and
then incubated with blocking solution (PBS with 8% bovine serum
albumin and 0.05% Tween 20) at room temperature for 30 min. Bcl-xL
protein was detected using a mouse monoclonal anti-rat Bcl-x antibody
(B22620, clone 4; Transduction Laboratories, Becton Dickinson,
Lexington, KY) diluted 1:200, Bim was detected using a rat monoclonal
anti-mouse Bim antibody recognizing BimEL,
BimL, and BimS (MAB17001, clone 14A8; Chemicon, Temecula, CA) diluted 1:100, Bax was detected using a rabbit polyclonal anti-human Bax antibody recognizing active Bax (06-499; Upstate Biotechnology, Lake Placid, NY) (34) diluted 1:500, and Bak was
detected using a rabbit polyclonal anti-human Bak antibody (sc-832,
G-23; Santa Cruz Biotechnology, Heidelberg, Germany) diluted 1:500.
After incubation at room temperature for 1 h, cells were washed
and incubated with biotin-conjugated goat anti-mouse or anti-rat IgG
antibody (Vector Laboratories, Burlingame, CA) diluted 1:1,000. The
secondary antibody was detected using Oregon Green-conjugated
streptavidin (Molecular Probes) diluted 1:1,000. Rabbit polyclonal
antibodies were detected using Texas Red-conjugated goat anti-rabbit
IgG (Molecular Probes), diluted 1:1,000. Control cultures were
incubated with secondary antibody only. Immunofluorescence was viewed
with the Eclipse TE 300 microscope with the following optics: Oregon
Green, excitation, 465-495 nm; dichroic mirror, 505 nm; emission,
515-555 nm; Texas Red, excitation 510-560 nm; dichroic mirror, 575 nm; emission, >590 nm. Digital images of equal exposure were acquired
using the SPOT-2 camera.
Transient Transfection Experiments--
To generate
pEGFP-C1-Bcl-xL, the complete open reading frame of the human Bcl-xL
gene (35) was amplified with primers
5'-TTAGATCTATGTCTCAGAGCAACCGGGAG-3' and
5'-TTGAATTCGGTGGGAGGGTAGAGTGG-3' using Pfu Polymerase (Promega). The
obtained PCR product was digested with BglII and
EcoRI and cloned between the BglII and
EcoRI sites of pEGFP-C1 (CLONTECH, Palo
Alto, CA). For transfections, INS-1 cells were plated onto 24-well
tissue culture plates. One day later cells were transfected with
plasmids pEGFP-C1-Bcl-xL or pEGFP-C1 using the F2 transfection reagent
(Targeting Systems, Santee, CA). 300 ng of plasmid DNA and 0.3 µl of
F2 reagent were diluted in 200 µl of RPMI medium under serum-free
conditions and preincubated at room temperature for 20 min. Cultures
were incubated with the DNA/F2-transfection mixture at 37 °C for
1 h. After 24 h, the culture medium was supplemented with 500 ng/ml doxycycline to induce DN-HNF-1 expression. After a further
48 h, nuclei were stained live with Hoechst 33258. Apoptotic nuclei and expression of Bcl-xL-EGFP and EGFP were observed by epifluorescence microscopy as described above. In co-transfection experiments, INS-1 cells were transfected with pEGFP-C1 (40 ng) and
either pSFFV-Neo or pSFFV-Bcl-xL (280 ng) (35).
Statistics--
Data are given as mean ± S.E. For
statistical comparison, ANOVA and subsequent Tukey's test were
employed. p Values smaller than 0.05 were considered to be
statistically significant.
 |
RESULTS |
INS-1 Cells Subjected to Prolonged Suppression of HNF-1 Function
Undergo Apoptotic Cell Death--
Using a reverse
tetracycline-dependent transactivator system we have previously
shown that dominant-negative suppression of HNF-1 function inhibits
the expression of HNF-1 target genes involved in glucose and lipid
homeostasis (15, 28). In subsequent experiments, we noted that under
conditions of prolonged induction of DN-HNF-1 (>48 h), INS-1 cells
frequently detached from the substratum and floated in the culture
medium. Floating cells exhibited a round, shrunken morphology
reminiscent of apoptosis, suggesting that dominant-negative suppression
of HNF-1 may have also influenced the expression of genes involved
in the regulation of apoptosis. To investigate the relationship between
induction of DN-HNF-1 and alterations in cell morphology in more
detail, expression of WT-HNF-1 and DN-HNF-1 was induced in INS-1
cells by treatment with doxycycline for 6, 14, 24, 48, and 60 h.
Apoptotic cell morphology was assessed in parallel by Hoechst staining
of nuclear chromatin. Treatment with 500 ng/ml doxycycline led to a
rapid induction of WT-HNF-1 and DN-HNF-1 in INS-1 cells stably
transfected with the reverse tetracycline-dependent
transactivator system, displaying similar kinetics (Fig.
1, A and B). In
each case, significant induction was already evident after 14 h of
doxycycline treatment. Nuclei of non-induced control cells exhibited a
regular, oval shape and a septate pattern of blue fluorescence (Fig. 1,
C and D). The nuclear morphology of INS-1 cells
remained unchanged at 6 and 14 h after induction of DN-HNF-1
(not shown). Twenty-four h after doxycycline treatment, the majority of
cells induced to overexpress DN-HNF-1 also displayed regular nuclear
Hoechst staining and a normal cell morphology (Fig. 1D).
Occasionally, however, we detected cells with a typical nuclear
apoptotic morphology characterized by increased chromatin condensation
and nuclear fragmentation. By 48 h, apoptotic nuclear changes
became visible in many DN-HNF-1 -expressing INS-1 cells. By 60 h, non-apoptotic, apoptotic, late-stage apoptotic/enucleated cells, as
well as floating cells could be detected in the cultures (not shown).
Induction of WT-HNF-1 for 24, 48, or 60 h, in contrast, did not
lead to any significant changes in nuclear morphology (Fig.
1C and data not shown). These results suggested that
prolonged, dominant-negative suppression of HNF-1 function is
sufficient to trigger apoptosis in INS-1 cells.

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 1.
Induction of DN-HNF-1
induces apoptosis in INS-1 cells. Time course of induction
of WT-HNF-1 (A) and DN-HNF-1 (B) in
response to 500 ng/ml doxycycline. Fifty µg of protein extract was
separated by 10% SDS-PAGE, proteins were blotted, and immunodetection
was performed using an anti-HNF-1 antibody. Locations of molecular
weight marker bands (in kDa) are provided on the left side
of the figure. Membranes were stripped and reprobed with an
anti- -tubulin antibody. Phase-contrast images and corresponding
Hoechst 33258 staining of nuclei in INS-1 cells induced to express
WT-HNF-1 (C) or DN-HNF-1 (D) for 0, 24, and
48 h. Non-induced controls show a smooth cell surface and a
septate pattern of blue Hoechst fluorescence. Note cell shrinkage,
membrane blebbing, and chromatin condensation and fragmentation in
cells overexpressing DN-HNF-1 . Scale bar = 10 µm.
|
|
Apoptotic Cell Death Induced by Dominant-negative Suppression of
HNF-1 Function Involves Activation of Executioner
Caspases--
Caspases play a central role in the activation and
execution of apoptotic cell death. Based on their structure and
substrate specificity, caspases can be subdivided into three
subfamilies: (i) upstream or apical caspases containing a large
NH2-terminal region and specific motifs that are required
for their aggregation and autoactivation; (ii) downstream or effector
caspases that are responsible for the execution of apoptotic cell
death; and (iii) caspases involved in the maturation of
pro-inflammatory cytokines (36). To assess whether activation of
executioner caspases was involved in DN-HNF1 -induced cell death, we
measured caspase activity by monitoring the cleavage of a fluorigenic
caspase substrate by extracts from doxycycline-treated INS-1 cells.
Ac-DEVD-AMC is cleaved most efficiently by caspase-3, the major
executioner caspase in most cell types, but also by other executioner
caspases (30). Production of the fluorescent cleavage product AMC was negligible with extracts from non-induced INS-1 cells equaling 3.55 ± 0.35 A.U./µg of protein and h (Fig.
2A). By 24 h of induction of DN-HNF1- , there was a very moderate but significant increase in
cleavage activity to 7.21 ± 0.71 A.U./µg of protein and h. By
48 h, caspase activity reached a maximum of 33.71 ± 0.86 A.U./µg of protein and h, an ~10-fold increase compared with
non-induced control. Cleavage activity remained elevated at 60 h
of doxycycline treatment. In contrast, induction of WT-HNF-1 for up
to 60 h did not cause significant caspase activity in the cultures
(Fig. 2A), at any time point. Parental INS-1 cells exposed
to doxycycline also failed to exhibit any increase in cleavage activity
(Fig. 2A).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 2.
Activation of caspases during
DN-HNF-1 -induced apoptosis.
A, time course of caspase-3-like protease activity in
cytosolic protein extracts. INS-1 cells were induced to overexpress
WT-HNF-1 or DN-HNF-1 for 0, 24, 48, and 60 h. As a control,
parental INS-1 cells were exposed to doxycycline for up to 60 h.
Caspase protease activity was measured by cleavage of the fluorigenic
substrate Ac-DEVD-AMC (10 µM). Activities are represented
as increase in AMC fluorescence (in A.U.) over 1 h per µg of
protein. Data are mean ± S.E. from n = 6 cultures. Experiments were repeated twice with similar results.
Different from non-induced controls: *, p < 0.05. B, detection of the active caspase-3 p17 subunit by Western
blot analysis. As a positive control, cells were exposed for 6 h
to the apoptosis-inducing kinase inhibitor STS (3 µM).
Membrane was stripped and reprobed with an anti- -tubulin antibody to
prove equal loading of samples. A duplicate experiment yielded
comparable results. C, treatment with the broad-spectrum
caspase inhibitor zVAD-fmk (100 µM) inhibits chromatin
fragmentation after induction of DN-HNF-1 . Cultures were
simultaneously treated with doxycycline and zVAD-FMK or vehicle
(dimethyl sulfoxide; -zVAD-fmk). After 48 h, nuclei were stained
with Hoechst 33258. Arrows indicate the presence of nuclear
fragmentation. Scale bar = 20 µm.
|
|
We also obtained direct evidence of caspase-3 activation by Western
blotting experiments. During apoptosis, caspase-3 is proteolytically activated by cleavage of its 32-kDa precursor into active subunits. We
observed the appearance of the active p17 subunit during the induction
of DN-HNF-1 (Fig. 2B). In contrast, the p17 subunit could
not be detected after induction of WT-HNF-1 (Fig. 2B). Both cell lines, however, were able to activate caspase-3 in
response to the apoptosis-inducing protein kinase inhibitor, STS, a
potent pro-apoptotic stimulus (Fig. 2B).
Further evidence for the involvement of caspases in DN-HNF-1 -induced
apoptosis was provided by examining the effect of the broad-spectrum
caspase inhibitor, zVAD-fmk. A simultaneous treatment with 100 µM zVAD-fmk potently inhibited nuclear fragmentation examined 48 h after the induction of DN-HNF-1 (Fig. 2,
C and D).
Activation of the Mitochondrial Apoptosis Pathway in
DN-HNF-1 -induced Apoptosis: Mitochondrial Hyperpolarization Precedes
Cytochrome c Release--
The release of pro-apoptotic factors, such
as cytochrome c, from the mitochondrial intermembrane space
into the cytosol represents a central coordinating step in apoptosis
(37). Cytoplasmic accumulation of pro-apoptotic cytochrome c
induces a caspase activating, multiprotein complex, the apoptosome (38,
39). Evidence has been provided that mitochondrial hyperpolarization is
an early event in trophic factor deprivation-, UV-, and STS-induced
apoptosis, preceding the release of pro-apoptotic factors such as
cytochrome c from mitochondria (40-44). We used the
potential-sensitive probe JC-1 in combination with confocal laser
scanning microscopy to evaluate changes in mitochondrial membrane
potential during DN-HNF-1 -induced apoptosis. Twenty-four h after
addition of doxycycline, mitochondrial hyperpolarization could be
detected in the majority of INS-1 cells, preceding the gross activation
of executioner caspases (Fig. 3, A and B). After 48 h of induction, cells
with shrunken somata and depolarized mitochondria could also be
detected (Fig. 3A). This finding is in agreement with
previous studies showing that mitochondria eventually depolarize after
the release of cytochrome c and activation of the caspase
cascade (41, 45, 46). The mitochondrial membrane potential of cells
induced to overexpress WT-HNF-1 did not change significantly up to
60 h after onset of the doxycycline treatment (data not
shown).

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 3.
Mitochondrial membrane hyperpolarization and
cytochrome c release during
DN-HNF-1 -induced apoptosis.
A, confocal JC-1 fluorescence images of INS-1 cells induced
to express DN-HNF-1 for 0, 24, or 48 h. The overlay of the two
emission wavelengths of the membrane potential-sensitive probe JC-1
shows a red shift in the confocal scans between 0 and 24 h,
indicative of mitochondrial hyperpolarization. After 48 h, a
heterogeneous state is detected with cells exhibiting depolarized
mitochondria (green fluorescence) or complete loss of JC-1
fluorescence, and cells exhibiting hyperpolarized mitochondria (yellow
to red fluorescence). Scale bars: 50 µm (upper
panel) and 10 µm (lower panel). B,
quantification of JC-1 fluorescence changes. The ratio of the red and
green fluorescence emission was obtained from three individual scans
and calculated from n = 210-273 cells. Different from
non-induced controls: *, p < 0.05. The experiment was
repeated twice with similar results. C, cytochrome
c release into the cytosol during DN-HNF-1 -induced
apoptosis. INS-1 cells were induced to overexpress WT- or DN-HNF-1
for 0, 24, and 48 h and were then subjected to digitonin
permeabilization of the plasma membrane (250 µg/ml, 4 °C) for 5 min. Soluble cytochrome c was detected in the supernatant by
Western blot analysis. As a positive control, non-induced INS-1 cells
were exposed to STS (3 µM, 6 h). Membrane was
stripped and reprobed with an anti- -tubulin antibody to prove equal
loading of samples. The experiment was performed three times with
similar results. D, detection of the active caspase-9 p18
subunit during DN-HNF-1 -induced apoptosis. A duplicate experiment
yielded comparable results.
|
|
Mitochondrial hyperpolarization after induction of DN-HNF-1 was
followed by the release of the pro-apoptotic factor cytochrome c from mitochondria (Fig. 3C). Using selective
digitonin permeabilization of the plasma membrane, cytosolic
accumulation of cytochrome c could be detected after 48 and
60 h of doxycycline treatment. No significant cytochrome
c release could be detected in cells expressing WT-HNF-1 .
After its release into the cytosol, cytochrome c is capable
of binding to the apoptotic protease-activating factor 1 (39). This
complex activates procaspase-9 in the presence of dATP, resulting in
apoptosome formation and activation of executioner caspases such as
caspase-3 (38, 39). In agreement with previous reports demonstrating
significant autoactivation of procaspase-9 even in unstimulated cells
(47), non-induced controls exhibited detectable levels of the active,
large p18 subunit of caspase-9 (Fig. 3D). Induction of
DN-HNF-1 led to signficant accumulation of the p18 active subunit
after 48 and 60 h, while cells overexpressing WT-HNF-1 did not
show such an increase (Fig. 3D).
Altered Gene Expression of Bcl-xL and p27KIP1 during
Dominant-negative Suppression of HNF-1 Function--
Release of
pro-apoptotic factors from mitochondria requires a selective outer
membrane permeability increase that is triggered and controlled by pro-
and anti-apoptotic Bcl-2 family proteins (37). We next investigated the
expression of Bcl-2 family members during DN-HNF-1 -induced
apoptosis. Bax is a pro-apoptotic Bcl-2 family member believed to be a
structural component of the mitochondrial outer membrane release
channel (37). Expression of bax mRNA was not altered
48 h after induction of DN-HNF-1 (Fig.
4A). Moreover, bax
gene expression was not sensitive to alterations in glucose concentration, both in induced and non-induced cells. Bax protein levels also remained unchanged, and similar results were obtained with
the pro-apoptotic Bax homolog Bak (data not shown). Nevertheless, we
obtained evidence for Bax activation during
DN-HNF-1 -induced apoptosis detected with a polyclonal antibody that
recognizes a conformational change in Bax required for its
pro-apoptotic activity (Fig. 4B) (34). Bax activation could
also be detected in response to 3 µM STS (Fig.
4B).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 4.
Altered expression of genes involved in
apoptosis and cell cycle regulation during
DN-HNF-1 -induced apoptosis. A,
Northern blot analysis of gene expression in DN-HNF-1 cells induced
with doxycycline for 48 h. Cultures were continued for 8 h at
the indicated glucose concentrations. After this period, total RNA was
extracted and samples were hybridized with the indicated cDNA
probes. B, detection of Bax activation by immunofluorescence
analysis using a polyclonal antibody recognizing a conformational
change in Bax required for its pro-apoptotic activity. INS-1 cells were
induced to overexpress DN-HNF-1 in the presence of 12 mM
glucose for 48 h or were exposed to 3 µM STS for
6 h. C, decrease in Bcl-xL protein expression during
DN-HNF-1 -induced apoptosis detected by immunofluorescence analysis
using a monoclonal antibody. INS-1 cells were induced to overexpress
WT- or DN-HNF-1 for 48 h in the presence of 12 mM
glucose, both in the absence or presence of the caspase inhibitor
zVAD-fmk (100 µM). Scale bar = 10 µm.
|
|
Of note, expression of the anti-apoptotic Bcl-2 family member Bcl-xL
decreased significantly after DN-HNF-1 induction (Fig. 4A). Bcl-xL mRNA expression was regulated by glucose in
induced and non-induced cultures, with increasing levels at increasing glucose concentrations. However, DN-HNF-1 expressing cells showed a
decreased response to glucose for Bcl-xL mRNA expression compared with non-induced cells. The decrease in Bcl-xL expression upon induction of DN-HNF-1 could also be detected on the protein level (Fig. 4C). Cultures treated with the caspase inhibitor
zVAD-FMK also showed this decrease, suggesting that this was not due to caspase-mediated degradation of Bcl-xL (48). Cells expressing WT-HNF-1 did not exhibit a decrease in Bcl-xL expression (Fig. 4C).
We next investigated the expression of pro-apoptotic Bcl-2 family
members of the Bcl-2-homology domain BH3-only family during the
induction of DN-HNF-1 . These proteins are believed to neutralize the
anti-apoptotic activity of Bcl-2 and Bcl-xL via direct protein-protein interactions, hence sensitizing cells to Bax- or Bak-mediated cytochrome c release (49). The expression of the BH3-only
members Bad, Bid, and Bim remained unchanged during the induction of
DN-HNF-1 (Fig. 4A and data not shown). However, by a
screen of other genes involved in cell cycle and apoptosis regulation,
we found that induction of DN-HNF-1 also led to a dramatic increase
in the expression of the cell cycle inhibitor p27KIP1, most
notable at low glucose concentrations (Fig. 4A). Expression of p21WAF1, a second cell cycle inhibitor and an important
p53 target gene, was slightly increased at the highest glucose
concentration. However, induction of DN-HNF-1 did not potentiate
p21WAF1 mRNA expression.
Overexpression of Bcl-xL Is Sufficient to Inhibit
Apoptosis Induction by DN-HNF-1 --
Evidence has been provided
that Bcl-xL inhibits cytochrome c release during apoptosis
(40). We were therefore interested to determine whether overexpression
of Bcl-xL was able to reverse DN-HNF-1 -induced cell death. INS-1
cells were transfected with plasmids encoding an EGFP-Bcl-xL fusion
protein or EGFP alone (controls). Twenty-four h after the transfection,
expression of DN-HNF-1 was induced for time periods of 48 and
60 h. Cells were assessed for apoptosis by counterstaining with
Hoechst 33258. Overexpression of EGFP-Bcl-xL potently inhibited
apoptosis induction in cultures exposed for 48 or 60 h to
doxycycline compared with the EGFP-transfected controls (Fig.
5). Similar results were obtained in
INS-1 cells transiently co-transfected with the EGFP vector and either
plasmid pSFFV-Neo (controls) or pSFFV-Bcl-xL (apoptosis rate after
48 h: 6.5 ± 1.5% in non-induced pSFFV-Neo-transfected cells, 3.0 ± 1.8% in non-induced pSFFV-Bcl-xL-transfected cells, 72.3 ± 2.9% in DN-HNF-1 -expressing cells transfected with
pSFFV-Neo, and 21.2 ± 5.4% in DN-HNF-1 -expressing cells
transfected with pSFFV-Bcl-xL; n = 3 cultures; a
duplicate experiment yielded comparable results).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 5.
Overexpression of Bcl-xL prevents
DN-HNF-1 -induced apoptosis. A,
Bcl-xL-EGFP or EGFP (control) were transiently transfected into INS-1
cells by lipofection. After 24 h, expression of DN-HNF-1 was
induced for 48 h. Live cells were counterstained with Hoechst
33258 and analyzed by epifluorescence and phase contrast microscopy.
Note the absence of chromatin condensation and fragmentation in cells
expressing Bcl-xL-EGFP. Scale bar = 20 µm.
B, quantitative analysis of nuclear apoptosis in
Bcl-xL-EGFP- and EGFP-transfected INS-1 cells induced to overexpress
DN-HNF-1 for 48 or 60 h. Non-induced cells served as controls.
All GFP-positive cells per culture (~100 cells) were assessed for
apoptotic nuclear morphology. Data are mean ± S.E. from
n = 5-6 cultures in three separate transfection
experiments. Different from respective non-induced controls: *,
p < 0.05. Difference between Bcl-xL-EGFP- and
EGFP-transfected cultures: #, p < 0.05.
|
|
DN-HNF-1 Sensitizes INS-1 Cells to Ceramide-, but Not to High
Glucose-induced Apoptosis--
We were finally interested to determine
whether a transient inhibition of HNF-1 function was sufficient to
sensitize INS-1 cells to glucose- or ceramide-induced apoptosis. In a
first set of experiments, expression of WT- or DN-HNF-1 was induced
for 24 h in the presence of 0, 2, 5, 10, 17.5, or 25 mM glucose. After this time period, a caspase activity
assay was performed to quantify the activation of executioner caspases.
In both cell lines, exposure to 0 mM glucose led to a
significant increase in caspase activity compared with cells cultured
at 5 or 10 mM glucose (Fig.
6A). However, the increase in
apoptosis was potentiated in DN-HNF-1 -expressing cells. Exposure to
high glucose (17.5 and 25 mM) did not induce apoptosis in
either cell line.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 6.
DN-HNF-1 sensitizes
INS-1 cells to ceramide, but not to high glucose-induced cell death.
A, expression of WT- or DN-HNF-1 was induced in the
presence of 0-25 mM D-glucose for 24 or
48 h. Cytosolic protein extracts were prepared and caspase-3-like
protease activity was measured using the fluorigenic substrate
Ac-DEVD-AMC. Data are mean ± S.E. from n = 4 cultures. Difference in caspase activity from corresponding cultures
exposed to 10 mM glucose: *, p < 0.05. Difference between WT- and DN-HNF-1 -induced INS-1 cells at identical
glucose concentrations: #, p < 0.05. n.a.,
not analyzed. The experiment was performed in duplicate with similar
results. B, effect on ceramide toxicity. Expression of WT-
or DN-HNF-1 was induced for either 14 or 24 h. During the last
4 h, the culture medium was supplemented with C2-ceramide or
vehicle (dimethyl sulfoxide), and a caspase activity assay was
performed. Data are mean ± S.E. from n = 6 cultures. Different from non-induced controls: *, p < 0.05. A duplicate experiment yielded comparable results. C,
expression of WT- or DN-HNF-1 was induced for 24 h. During the
last 4 h, the culture medium was supplemented with 100 µM C2-ceramide, 100 µM C2-dihydroceramide
or vehicle (dimethyl sulfoxide). Cells were stained live with Hoechst
33258 (detection of nuclear apoptosis) and propidium iodide (detection
of membrane leakage). A total of 120-150 cells were analyzed per
culture. Data are mean ± S.E. from n = 4 cultures. Different from non-induced controls: *, p < 0.05. D, nuclear morphology of C2-ceramide and
C2-dihydroceramide-treated INS-1 cells visualized with
Hoechst 33258. Cells were treated as described in
C. Scale bar, 10 µm.
|
|
In a second experiment, expression of WT- and DN-HNF-1 was induced
for 48 h (Fig. 6A). Cells overexpressing WT-HNF-1
showed increased apoptosis at 0 and 25 compared with 5 and 10 mM glucose. DN-HNF-1 expressing cells showed
significantly higher apoptosis activation at 2, 5, 10, and 17.5 mM glucose compared with WT-HNF-1 -expressing cells.
However, there was no statistically significant difference in the
extent of apoptosis induction by 25 mM glucose between WT-
and DN-HNF-1 -expressing cells. DN-HNF-1 -expressing cells cultured
at 0 mM glucose could not be analyzed after 48 h,
since most cells had already detached from the culture dish.
Ceramide toxicity has been shown to mediate fatty acid-induced
apoptosis in -cells (25, 50). We finally investigated the effect of
an exposure to C2-ceramide in WT- and DN-HNF-1 -expressing INS-1
cells (Fig. 6B). Cells were induced to express WT- or
DN-HNF-1 for 14 and 24 h. During the last 4 h, cells were
treated with 50 or 100 µM C2-ceramide, and a caspase
activity assay was performed. Interestingly, exposure to 100 µM C2-ceramide potently activated apoptosis in the cells
overexpressing DN-HNF-1 for 24 h. Pronounced activation of
caspases could already be detected in C2-ceramide-treated cultures
induced to overexpress DN-HNF-1 for 14 h. In contrast, C2-ceramide only induced a very modest caspase activation in cells overexpressing WT-HNF-1 for 24 h.
In a second experiment, we simultaneously determined nuclear apoptosis
(Hoechst staining of nuclear chromatin) and cellular necrosis (membrane
leakage visualized by uptake of the membrane-impermeant dye propidium
iodide) in response to C2-ceramide in living cells. Cells were induced
to express WT- or DN-HNF-1 for 24 h. C2-ceramide (100 µM), the biologically less active C2-dihydroceramide (100 µM), or vehicle was added during the last 4 h.
Exposure to C2-ceramide selectively induced apoptosis in the
DN-HNF-1 -expressing cells (Fig. 6, C and
D). Control experiments using C2-dihydroceramide showed that
nonspecific detergent effects could be excluded.
 |
DISCUSSION |
The present study demonstrates several important findings that may
help in the understanding of -cell dysfunction in subjects with
MODY3. These include (i) prolonged suppression of HNF-1 function is
sufficient to activate the evolutionary conserved apoptotic cell death
program in insulin-secreting cells; (ii) overexpression of DN-HNF-1
leads to decreased expression of the central survival protein Bcl-xL;
(iii) sensitizes the cell to ceramide-, but not to high glucose-induced
apoptosis; and (iv) leads to increased expression of the
cyclin-dependent kinase inhibitor p27KIP1.
HNF-1 has been shown to trans-activate the rat insulin I
gene promoter (9, 51). Overexpression of the SM6 and P291fsinsC HNF-1 mutants in INS-1 insulinoma cells resulted in impaired insulin
gene transcription (15, 28). Similar findings have been obtained by
overexpression of a dominant-negative mutant of HNF-4 (52).
Interestingly, insulin transcription is not completely suppressed in
cells carrying a dominant-negative or null HNF-1 mutation (12, 28),
suggesting that the insulin gene is also regulated by other
transcription factors (11). The expression of insulin-like growth
factors I and II is also reduced in HNF-1 -deficient mice (12).
Defective insulin/insulin-like growth factor signaling through the PI
3-kinase and Akt kinase pathway may play a prominent role in
DN-HNF-1 -induced apoptosis. Akt kinase is able to phosphorylate and
inactivate several pro-apoptotic proteins, such as Bad and caspase-9
(53, 54). Other effects of PI 3-kinase and Akt kinase include
phosphorylation-dependent regulation of transcription
factors of the Forkhead and cAMP-response- element-binding protein
families, leading to reduced transcription of pro- (55), and enhanced
transcription of anti-apoptotic genes (56, 57). Interestingly, the
Forkhead transcription factor FKHR-L1 has also been shown to
down-regulate the expression of the cell cycle inhibitor
p27KIP1 in a PI 3-kinase-dependent manner (58).
Reduced insulin or insulin-like growth factor signaling through PI
3-kinase could therefore also play a role in the increase in
p27KIP1 expression observed in the DN mutant cells. The PI
3-kinase/Akt kinase pathway has also been implicated in the activation
of transcription factor nuclear factor- B (NF- B) (59, 60). Binding
sites for the active NF- B subunits p65/relA and c-rel have
been demonstrated by functional analysis of the bcl-x
promoter (61, 62). It is therefore conceivable that the reduction in
Bcl-xL expression upon induction of DN-HNF-1 is caused by reduced
activation of the PI 3-kinase/Akt kinase/NF- B pathway.
Overexpression of Bcl-xL in INS-1 cells potently inhibited
DN-HNF-1 -induced apoptosis, demonstrating the importance of Bcl-xL
in maintaining -cell survival.
Bcl-xL inhibits apoptosis by preventing the release of pro-apoptotic
factors from the mitochondrial intermembrane space into the cytosol
(37). Bcl-xL may act to directly inhibit the formation of a megachannel
in the outer mitochondrial membrane or may indirectly inhibit pore
formation by neutralizing pro-apoptotic BH3-only family members.
Although we detected Bax activation after the induction of DN-HNF-1 ,
the expression of Bax and Bak, as well as the expression of the
BH3-only family members Bad, Bid, and Bim were unaltered. As a
reduction in Bcl-xL expression may be per se sufficient to
activate apoptosis (63, 64), our data point to an important role for
HNF-1 in maintaining -cell viability. The survival-supporting
role of HNF-1 may not be confined to -cells, as homozygous
HNF-1 knock-out mice also show increased degeneration of hepatocytes
and defects in spermatogenesis (12). Moreover, the pathophysiological
hyperpolarization of mitochondria observed after induction of
DN-HNF-1 may also explain the reduced ability of glucose to
hyperpolarize mitochondria and hence to stimulate and coordinate
insulin secretion in these cells (15, 28).
Both an elevated glucose concentration as well as increased formation
of free fatty acids have been suggested to contribute to a
pathophysiological decline in -cell mass by influencing -cell
proliferation and -cell apoptosis (25, 65, 66). Exposure to high
glucose has previously been shown to activate apoptosis in cultured
mouse, rat, and human islets (66, 67). Expression of
DN-HNF-1 -induced apoptosis over a broad glucose range (2-17.5
mM) compared with WT-HNF-1 -expressing cells. However, a
potentiating effect of high glucose was not obvious in the
DN-HNF-1 -expressing cells. In contrast, there was reduced apoptosis
activation at 17.5 and 25 mM glucose. It is conceivable
that increased bcl-xL mRNA expression at high glucose
concentrations exerted a protective effect in the DN-HNF-1
expressing cells.
WT-HNF-1 -expressing cells also activated apoptosis at 25 mM glucose (Fig. 6A), as did parental INS-1
cells.2 There was no
statistically significant difference in the extent of apoptosis
activation at 25 mM glucose between WT- and
DN-HNF-1 -expressing cells. Our data therefore suggest that high
glucose activates a cell death pathway that is not influenced by
DN-HNF-1 . A recent study has shown that high glucose-induced
apoptosis involved the activation of the death receptor pathway in
-cells via up-regulation of Fas receptor expression and activation
of initiator caspase-8 (66). The activation of the mitochondrial
pathway was unimportant as cytochrome c release could not be
detected in response to high glucose. As shown in the present study,
DN-HNF-1 activated the mitochondrial apoptosis pathway. Hence it is
conceivable that high glucose and expression of DN-HNF-1 induce
distinct cell death pathways.
In contrast, we observed a significant potentiation of zero glucose and
in particular ceramide-induced apoptosis after overexpression of
DN-HNF-1 . These findings suggest that these stimuli also induce the
activation of the mitochondrial apoptosis pathway. Indeed, it has
previously been shown that saturated fatty acids activate the
mitochondrial apoptosis pathway (65), and that maintenance of Bcl-2
expression rescued -cells from free fatty acid-induced apoptosis
(25). C2-ceramide has been shown to impair insulin-induced signal
transduction via the insulin-dependent membrane recruitment of Akt kinase (68). It is therefore conceivable that C2-ceramide and
induction of DN-HNF-1 resulted in a potentiation of the inhibition of a central survival pathway. These results are also in accordance with the general role of HNF-1 in the control of lipid metabolism, and the -cell protective effects of agents such as
thiazolidinediones that influence lipid metabolism in animal models of
NIDDM (25, 27, 69).
Previous studies in normal rats have demonstrated that a 96-h
intravenous glucose infusion resulted in significant increases in
-cell mass due to neogenesis and hypertrophy (70) (see also Ref.
26). Interestingly, we observed decreased expression of the cell cycle
inhibitor p27KIP1 at higher glucose concentrations in
non-induced INS-1 cells. This adaptive response was still present,
although reduced in cells overexpressing DN-HNF-1 . There is evidence
for similar adaptive responses in prediabetic MODY3 subjects. After a
42-h glucose infusion resulting in mild hyperglycemia (~7
mM), there was a 32% increase in insulin secretion in
MODY3 compared with control subjects (3). This adaptive response may
not only be caused by an increase in -cell proliferation, but also
by an increased performance of individual -cells. Prediabetic
subjects with MODY 3 secrete adequate if not higher amounts of insulin at glucose levels <8 mM (3) and may exhibit
hyperexcitability to sulfonylureas (71). Nevertheless, it is tempting
to speculate that mild hyperglycemia may to some extent exert
protective effects in cells overexpressing DN-HNF-1 , by inhibiting
p27KIP1 induction and stimulating Bcl-xL expression. Over
time, however, accumulation of free fatty acids, increased ceramide
generation, as well as additive effects of glucotoxicity may render
-cells more vulnerable to cell death. Likewise, in the Zucker
diabetic fatty rat, -cell proliferation compensates for the
increased -cell loss at a time when plasma glucose is moderately
elevated, but this compensation ultimately fails and the plasma glucose levels increase further (27). An imbalance between -cell death and
neogenesis, in combination with decreased -cell compensation for
insulin resistance may eventually lead to diabetes in MODY3 patients.
 |
ACKNOWLEDGEMENTS |
We thank Christiane Schettler and Hanni
Bähler for technical assistance, Drs. D. W. Nicholson and R. Cortese for their kind supply of antibodies, and Drs. C. B. Thompson and L. H. Boise for Bcl-xL cDNA.
 |
FOOTNOTES |
*
This work was supported by IZKF Universität
Münster Grant BMBF 01 KS 9604/0 (to J. H. M. P.)
and Swiss National Science Foundation Grant 32-49755.96 (to C. B. W.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
These authors share equal senior authorship.
**
To whom correspondence should be addressed: Interdisciplinary
Center for Clinical Research (IZKF) Research Group "Apoptosis and
Cell Death," Faculty of Medicine, Westphalian Wilhelms-University Röntgenstrasse 21, D-48149 Münster, Germany. Tel.:
49-251-83-52251; Fax: 49-251-83-52250; E-mail:
prehn@uni-muenster.de.
Published, JBC Papers in Press, November 27, 2001, DOI 10.1074/jbc.M108390200
2
H. Wobser, C. Schettler, and J. H. M. Prehn, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
MODY, maturity onset
diabetes of the young;
HNF, hepatocyte nuclear factor;
INS-1, rat
insulinoma cells;
NIDDM, non-insulin-dependent diabetes
mellitus;
STS, staurosporine;
PBS, phosphate-buffered saline;
EGFP, epidermal growth factor protein;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid;
PI
3-kinase, phosphatidylinositol 3-kinase;
A. U., arbitrary
fluorescence units.
 |
REFERENCES |
| 1.
|
Fajans, S. S.,
Bell, G. I.,
Bowden, D. W.,
Halter, J. B.,
and Polonsky, K. S.
(1994)
Life Sci.
55,
413-422[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Hattersley, A. T.
(1998)
Diabet. Med.
15,
15-24[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Byrne, M. M.,
Sturis, J.,
Menzel, S.,
Yamagata, K.,
Fajans, S. S.,
Dronsfield, M. J.,
Bain, S. C.,
Hattersley, A. T.,
Velho, G.,
Froguel, P.,
Bell, G. I.,
and Polonsky, K. S.
(1996)
Diabetes
45,
1503-1510[Abstract]
|
| 4.
|
Byrne, M. M.,
Sturis, J.,
Fajans, S. S.,
Ortiz, F. J.,
Stoltz, A.,
Stoffel, M.,
Smith, M. J.,
Bell, G. I.,
Halter, J. B.,
and Polonsky, K. S.
(1995)
Diabetes
44,
699-704[Abstract]
|
| 5.
|
Ward, W. K.,
Wallum, B. J.,
Beard, J. C.,
Taborsky, G. J., Jr.,
and Porte, D., Jr.
(1988)
Diabetes
37,
723-729[Abstract]
|
| 6.
|
Leahy, J. L.,
Bumbalo, L. M.,
and Chen, C.
(1993)
Diabetologia
36,
1238-1244[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Frain, M.,
Swart, G.,
Monaci, P.,
Nicosia, A.,
Stampfli, S.,
Frank, R.,
and Cortese, R.
(1989)
Cell
59,
145-157[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Blumenfeld, M.,
Maury, M.,
Chouard, T.,
Yaniv, M.,
and Condamine, H.
(1991)
Development
113,
589-599[Abstract]
|
| 9.
|
De Simone, V., De,
Magistris, L.,
Lazzaro, D.,
Gerstner, J.,
Monaci, P.,
Nicosia, A.,
and Cortese, R.
(1991)
EMBO J.
10,
1435-1443[Medline]
[Order article via Infotrieve]
|
| 10.
|
Pontoglio, M.,
Barra, J.,
Hadchouel, M.,
Doyen, A.,
Kress, C.,
Bach, J. P.,
Babinet, C.,
and Yaniv, M.
(1996)
Cell
84,
575-585[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Pontoglio, M.,
Sreenan, S.,
Roe, M.,
Pugh, W.,
Ostrega, D.,
Doyen, A.,
Pick, A. J.,
Baldwin, A.,
Velho, G.,
Froguel, P.,
Levisetti, M.,
Bonner-Weir, S.,
Bell, G. I.,
Yaniv, M.,
and Polonsky, K. S.
(1998)
J. Clin. Invest.
101,
2215-2222[Medline]
[Order article via Infotrieve]
|
| 12.
|
Lee, Y. H.,
Sauer, B.,
and Gonzalez, F. J.
(1998)
Mol. Cell. Biol.
18,
3059-3068[Abstract/Free Full Text]
|
| 13.
|
Shih, D. Q.,
Bussen, M.,
Sehayek, E.,
Ananthanarayanan, M.,
Shneider, B. L.,
Suchy, F. J.,
Shefer, S.,
Bollileni, J. S.,
Gonzalez, F. J.,
Breslow, J. L.,
and Stoffel, M.
(2001)
Nat. Genet.
27,
375-382[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Yamagata, K.,
Yang, Q.,
Yamamoto, K.,
Iwahashi, H.,
Miyagawa, J.,
Okita, K.,
Yoshiuchi, I.,
Miyazaki, J.,
Noguchi, T.,
Nakajima, H.,
Namba, M.,
Hanafusa, T.,
and Matsuzawa, Y.
(1998)
Diabetes
47,
1231-1235[Abstract]
|
| 15.
|
Wang, H.,
Antinozzi, P. A.,
Hagenfeldt, K. A.,
Maechler, P.,
and Wollheim, C. B.
(2000)
EMBO J.
19,
4257-4264[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Lehto, M.,
Tuomi, T.,
Mahtani, M. M.,
Widen, E.,
Forsblom, C.,
Sarelin, L.,
Gullstrom, M.,
Isomaa, B.,
Lehtovirta, M.,
Hyrkko, A.,
Kanninen, T.,
Orho, M.,
Manley, S.,
Turner, R. C.,
Brettin, T.,
Kirby, A.,
Thomas, J.,
Duyk, G.,
Lander, E.,
Taskinen, M. R.,
and Groop, L.
(1997)
J. Clin. Invest.
99,
582-591[Medline]
[Order article via Infotrieve]
|
| 17.
|
Dukes, I. D.,
Sreenan, S.,
Roe, M. W.,
Levisetti, M.,
Zhou, Y. P.,
Ostrega, D.,
Bell, G. I.,
Pontoglio, M.,
Yaniv, M.,
Philipson, L.,
and Polonsky, K. S.
(1998)
J. Biol. Chem.
273,
24457-24464[Abstract/Free Full Text]
|
| 18.
|
Finegood, D. T.,
Scaglia, L.,
and Bonner-Weir, S.
(1995)
Diabetes
44,
249-256[Abstract]
|
| 19.
|
Koyama, M.,
Wada, R.,
Sakuraba, H.,
Mizukami, H.,
and Yagihashi, S.
(1998)
Am. J. Pathol.
153,
537-545[Abstract/Free Full Text]
|
| 20.
|
Kulkarni, R. N.,
Bruning, J. C.,
Winnay, J. N.,
Postic, C.,
Magnuson, M. A.,
and Kahn, C. R.
(1999)
Cell
96,
329-339[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Pick, A.,
Clark, J.,
Kubstrup, C.,
Levisetti, M.,
Pugh, W.,
Bonner-Weir, S.,
and Polonsky, K. S.
(1998)
Diabetes
47,
358-364[Abstract]
|
| 22.
|
Withers, D. J.,
Gutierrez, J. S.,
Towery, H.,
Burks, D. J.,
Ren, J. M.,
Previs, S.,
Zhang, Y.,
Bernal, D.,
Pons, S.,
Shulman, G. I.,
Bonner-Weir, S.,
and White, M. F.
(1998)
Nature
391,
900-904[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Pende, M.,
Kozma, S. C.,
Jaquet, M.,
Oorschot, V.,
Burcelin, R., Le,
Marchand-Brustel, Y.,
Klumperman, J.,
Thorens, B.,
and Thomas, G.
(2000)
Nature
408,
994-997[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Silva, J. P.,
Kohler, M.,
Graff, C.,
Oldfors, A.,
Magnuson, M. A.,
Berggren, P. O.,
and Larsson, N. G.
(2000)
Nat. Genet.
26,
336-340[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Shimabukuro, M.,
Zhou, Y. T.,
Levi, M.,
and Unger, R. H.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
2498-2502[Abstract/Free Full Text]
|
| 26.
|
Bernard, C.,
Berthault, M. F.,
Saulnier, C.,
and Ktorza, A.
(1999)
FASEB J.
13,
1195-1205[Abstract/Free Full Text]
|
| 27.
|
Finegood, D. T.,
McArthur, M. D.,
Kojwang, D.,
Thomas, M. J.,
Topp, B. G.,
Leonard, T.,
and Buckingham, R. E.
(2001)
Diabetes
50,
1021-1029[Abstract/Free Full Text]
|
| 28.
|
Wang, H.,
Maechler, P.,
Hagenfeldt, K. A.,
and Wollheim, C. B.
(1998)
EMBO J.
17,
6701-6713[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Nicosia, A.,
Monaci, P.,
Tomei, L., De,
Francesco, R.,
Nuzzo, M.,
Stunnenberg, H.,
and Cortese, R.
(1990)
Cell
61,
1225-1236[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Garcia-Calvo, M.,
Peterson, E. P.,
Rasper, D. M.,
Vaillancourt, J. P.,
Zamboni, R.,
Nicholson, D. W.,
and Thornberry, N. A.
(1999)
Cell Death Differ.
6,
362-369[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Smiley, S. T.,
Reers, M.,
Mottola-Hartshorn, C.,
Lin, M.,
Chen, A.,
Smith, T. W.,
Steele, G. D., Jr.,
and Chen, L. B.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
3671-3675[Abstract/Free Full Text]
|
| 32.
|
Leist, M.,
Volbracht, C.,
Fava, E.,
and Nicotera, P.
(1998)
Mol. Pharmacol.
54,
789-801[Abstract/Free Full Text]
|
| 33.
|
Black, S. C.,
Huang, J. Q.,
Rezaiefar, P.,
Radinovic, S.,
Eberhart, A.,
Nicholson, D. W.,
and Rodger, I. W.
(1998)
J. Mol. Cell Cardiol.
30,
733-742[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Desagher, S.,
Osen-Sand, A.,
Nichols, A.,
Eskes, R.,
Montessuit, S.,
Lauper, S.,
Maundrell, K.,
Antonsson, B.,
and Martinou, J. C.
(1999)
J. Cell Biol.
144,
891-901[Abstract/Free Full Text]
|
| 35.
|
Boise, L. H.,
Gonzalez-Garcia, M.,
Postema, C. E.,
Ding, L.,
Lindsten, T.,
Turka, L. A.,
Mao, X.,
Nunez, G.,
and Thompson, C. B.
(1993)
Cell
74,
597-608[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Nicholson, D. W.
(1999)
Cell Death Differ.
6,
1028-1042[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Desagher, S.,
and Martinou, J. C.
(2000)
Trends Cell Biol.
10,
369-377[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Li, P.,
Nijhawan, D.,
Budihardjo, I.,
Srinivasula, S. M.,
Ahmad, M.,
Alnemri, E. S.,
and Wang, X.
(1997)
Cell
91,
479-489[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Zou, H.,
Henzel, W. J.,
Liu, X.,
Lutschg, A.,
and Wang, X.
(1997)
Cell
90,
405-413[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Vander Heiden, M. G.,
Chandel, N. S.,
Williamson, E. K.,
Schumacker, P. T.,
and Thompson, C. B.
(1997)
Cell
91,
627-637[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Krohn, A. J.,
Wahlbrink, T.,
and Prehn, J. H.
(1999)
J. Neurosci.
19,
7394-7404[Abstract/Free Full Text]
|
| 42.
|
Kennedy, S. G.,
Kandel, E. S.,
Cross, T. K.,
and Hay, N.
(1999)
Mol. Cell. Biol.
19,
5800-5810[Abstract/Free Full Text]
|
| 43.
|
Khaled, A. R.,
Reynolds, D. A.,
Young, H. A.,
Thompson, C. B.,
Muegge, K.,
and Durum, S. K.
(2001)
J. Biol. Chem.
276,
6453-6462[Abstract/Free Full Text]
|
| 44.
|
Poppe, M.,
Reimertz, C.,
Dussmann, H.,
Krohn, A. J.,
Luetjens, C. M.,
Bockelmann, D.,
Nieminen, A. L.,
Kogel, D.,
and Prehn, J. H.
(2001)
J. Neurosci.
21,
4551-4563[Abstract/Free Full Text]
|
| 45.
|
Bossy-Wetzel, E.,
Newmeyer, D. D.,
and Green, D. R.
(1998)
EMBO J.
17,
37-49[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Goldstein, J. C.,
Waterhouse, N. J.,
Juin, P.,
Evan, G. I.,
and Green, D. R.
(2000)
Nat. Cell Biol.
2,
156-162[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Stennicke, H. R.,
Deveraux, Q. L.,
Humke, E. W.,
Reed, J. C.,
Dixit, V. M.,
and Salvesen, G. S.
(1999)
J. Biol. Chem.
274,
8359-8362[Abstract/Free Full Text]
|
| 48.
|
Clem, R. J.,
Cheng, E. H.,
Karp, C. L.,
Kirsch, D. G.,
Ueno, K.,
Takahashi, A.,
Kastan, M. B.,
Griffin, D. E.,
Earnshaw, W. C.,
Veliuona, M. A.,
and Hardwick, J. M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
554-559[Abstract/Free Full Text]
|
| 49.
|
Huang, D. C.,
and Strasser, A.
(2000)
Cell
103,
839-842[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Shimabukuro, M.,
Wang, M. Y.,
Zhou, Y. T.,
Newgard, C. B.,
and Unger, R. H.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9558-9561[Abstract/Free Full Text]
|
| 51.
|
Emens, L. A.,
Landers, D. W.,
and Moss, L. G.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
7300-7304[Abstract/Free Full Text]
|
| 52.
|
Wang, H.,
Maechler, P.,
Antinozzi, P. A.,
Hagenfeldt, K. A.,
and Wollheim, C. B.
(2000)
J. Biol. Chem.
275,
35953-35959[Abstract/Free Full Text]
|
| 53.
|
Datta, S. R.,
Dudek, H.,
Tao, X.,
Masters, S., Fu, H.,
Gotoh, Y.,
and Greenberg, M. E.
(1997)
Cell
91,
231-241[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Cardone, M. H.,
Roy, N.,
Stennicke, H. R.,
Salvesen, G. S.,
Franke, T. F.,
Stanbridge, E.,
Frisch, S.,
and Reed, J. C.
(1998)
Science
282,
1318-1321[Abstract/Free Full Text]
|
| 55.
|
Brunet, A.,
Bonni, A.,
Zigmond, M. J.,
Lin, M. Z.,
Juo, P., Hu, L. S.,
Anderson, M. J.,
Arden, K. C.,
Blenis, J.,
and Greenberg, M. E.
(1999)
Cell
96,
857-868[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Du, K.,
and Montminy, M.
(1998)
J. Biol. Chem.
273,
32377-32379[Abstract/Free Full Text]
|
| 57.
|
Riccio, A.,
Ahn, S.,
Davenport, C. M.,
Blendy, J. A.,
and Ginty, D. D.
(1999)
Science
286,
2358-2361[Abstract/Free Full Text]
|
| 58.
|
Dijkers, P. F.,
Medema, R. H.,
Pals, C.,
Banerji, L.,
Thomas, N. S.,
Lam, E. W.,
Burgering, B. M.,
Raaijmakers, J. A.,
Lammers, J. W.,
Koenderman, L.,
and Coffer, P. J.
(2000)
Mol. Cell. Biol.
20,
9138-9148[Abstract/Free Full Text]
|
| 59.
|
Ozes, O. N.,
Mayo, L. D.,
Gustin, J. A.,
Pfeffer, S. R.,
Pfeffer, L. M.,
and Donner, D. B.
(1999)
Nature
401,
82-85[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Romashkova, J. A.,
and Makarov, S. S.
(1999)
Nature
401,
86-90[CrossRef][Medline]
[Order article via Infotrieve]
|
| 61.
|
Chen, F.,
Demers, L. M.,
Vallyathan, V., Lu, Y.,
Castranova, V.,
and Shi, X.
(1999)
J. Biol. Chem.
274,
35591-35595[Abstract/Free Full Text]
|
| 62.
|
Lee, H. H.,
Dadgostar, H.,
Cheng, Q.,
Shu, J.,
and Cheng, G.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
9136-9141[Abstract/Free Full Text]
|
| 63.
|
Motoyama, N.,
Wang, F.,
Roth, K. A.,
Sawa, H.,
Nakayama, K.,
Negishi, I.,
Senju, S.,
Zhang, Q.,
Fujii, S.,
and Loh, D. Y.
(1995)
Science
267,
1506-1510[Abstract/Free Full Text]
|
| 64.
|
Zong, W. X.,
Lindsten, T.,
Ross, A. J.,
MacGregor, G. R.,
and Thompson, C. B.
(2001)
Genes Dev.
15,
1481-1486[Abstract/Free Full Text]
|
| 65.
|
Maedler, K.,
Spinas, G. A.,
Dyntar, D.,
Moritz, W.,
Kaiser, N.,
and Donath, M. Y.
(2001)
Diabetes
50,
69-76[Abstract/Free Full Text]
|
| 66.
|
Maedler, K.,
Spinas, G. A.,
Lehmann, R.,
Sergeev, P.,
Weber, M.,
Fontana, A.,
Kaiser, N.,
and Donath, M. Y.
(2001)
Diabetes
50,
1683-1690[Abstract/Free Full Text]
|
| 67.
|
Efanova, I. B.,
Zaitsev, S. V.,
Zhivotovsky, B.,
Kohler, M.,
Efendic, S.,
Orrenius, S.,
and Berggren, P. O.
(1998)
J. Biol. Chem.
273,
33501-33507[Abstract/Free Full Text]
|
| 68.
|
Hajduch, E.,
Balendran, A.,
Batty, I. H.,
Litherland, G. J.,
Blair, A. S.,
Downes, C. P.,
and Hundal, H. S.
(2001)
Diabetologia
44,
173-183[CrossRef][Medline]
[Order article via Infotrieve]
|
| 69.
|
Higa, M.,
Zhou, Y. T.,
Ravazzola, M.,
Baetens, D.,
Orci, L.,
and Unger, R. H.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
11513-11518[Abstract/Free Full Text]
|
| 70.
|
Bonner-Weir, S.,
Deery, D.,
Leahy, J. L.,
and Weir, G. C.
(1989)
Diabetes
38,
49-53[Abstract]
|
| 71.
|
Hansen, T.,
Eiberg, H.,
Rouard, M.,
Vaxillaire, M.,
Moller, A. M.,
Rasmussen, S. K.,
Fridberg, M.,
Urhammer, S. A.,
Holst, J. J.,
Almind, K.,
Echwald, S. M.,
Hansen, L.,
Bell, G. I.,
and Pedersen, O.
(1997)
Diabetes
46,
726-730[Abstract]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. G. Kim and S. J. Lee
PI3K, RSK, and mTOR Signal Networks for the GST Gene Regulation
Toxicol. Sci.,
April 1, 2007;
96(2):
206 - 213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. F. Luco, M. A. Maestro, N. del Pozo, W. M. Philbrick, P. P. de la Ossa, and J. Ferrer
A Conditional Model Reveals That Induction of Hepatocyte Nuclear Factor-1{alpha} in Hnf1{alpha}-Null Mutant {beta}-Cells Can Activate Silenced Genes Postnatally, Whereas Overexpression Is Deleterious.
Diabetes,
August 1, 2006;
55(8):
2202 - 2211.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. J Welters, S. Senkel, L. Klein-Hitpass, S. Erdmann, H. Thomas, L. W Harries, E. R Pearson, C. Bingham, A. T Hattersley, G. U Ryffel, et al.
Conditional expression of hepatocyte nuclear factor-1{beta}, the maturity-onset diabetes of the young-5 gene product, influences the viability and functional competence of pancreatic {beta}-cells.
J. Endocrinol.,
July 1, 2006;
190(1):
171 - 181.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J R Porter and T G Barrett
Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of insulin resistance and {beta} cell failure
J. Med. Genet.,
December 1, 2005;
42(12):
893 - 902.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Bardoux, P. Zhang, D. Flamez, A. Perilhou, T. A. Lavin, J.-F. Tanti, K. Hellemans, E. Gomas, C. Godard, F. Andreelli, et al.
Essential Role of Chicken Ovalbumin Upstream Promoter-Transcription Factor II in Insulin Secretion and Insulin Sensitivity Revealed by Conditional Gene Knockout
Diabetes,
May 1, 2005;
54(5):
1357 - 1363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Hinke, K. Hellemans, and F. C. Schuit
Plasticity of the {beta} cell insulin secretory competence: preparing the pancreatic {beta} cell for the next meal
J. Physiol.,
July 15, 2004;
558(2):
369 - 380.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I-N. Park, I. J. Cho, and S. G. Kim
Ceramide Negatively Regulates Glutathione S-transferase Gene Transactivation via Repression of Hepatic Nuclear Factor-1 That Is Degraded by the Ubiquitin Proteasome System
Mol. Pharmacol.,
June 1, 2004;
65(6):
1475 - 1484.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tsuchiya, M. Sakamoto, J. Yasuda, M. Chuma, T. Ohta, M. Ohki, T. Yasugi, Y. Taketani, and S. Hirohashi
Expression Profiling in Ovarian Clear Cell Carcinoma: Identification of Hepatocyte Nuclear Factor-1{beta} as a Molecular Marker and a Possible Molecular Target for Therapy of Ovarian Clear Cell Carcinoma
Am. J. Pathol.,
December 1, 2003;
163(6):
2503 - 2512.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
C. Reimertz, D. Kogel, A. Rami, T. Chittenden, and J. H.M. Prehn
Gene expression during ER stress-induced apoptosis in neurons: induction of the BH3-only protein Bbc3/PUMA and activation of the mitochondrial apoptosis pathway
J. Cell Biol.,
August 18, 2003;
162(4):
587 - 597.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wang, K. Hagenfeldt-Johansson, L. A. Otten, B. R. Gauthier, P. L. Herrera, and C. B. Wollheim
Experimental Models of Transcription Factor-Associated Maturity-Onset Diabetes of the Young
Diabetes,
December 1, 2002;
51(90003):
S333 - 342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Yang, K. Yamagata, K. Fukui, Y. Cao, T. Nammo, H. Iwahashi, H. Wang, I. Matsumura, T. Hanafusa, R. Bucala, et al.
Hepatocyte Nuclear Factor-1{alpha} Modulates Pancreatic {beta}-Cell Growth by Regulating the Expression of Insulin-Like Growth Factor-1 in INS-1 Cells
Diabetes,
June 1, 2002;
51(6):
1785 - 1792.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|